Announced details
Paramylon content of at least 70%. Existing purified paramylon has a content of at least 80%. A 12-week intake study involving healthy adult men and women reported suppression of cold-like symptoms, maintenance of CD80 expression on monocytes, and increased CD28 expression on CD4⁺/CD8⁺ naive T cells.
Business transfer from Kobelco Eco-Solutions to euglena. Kobelco Eco-Solutions is the transferor, and euglena is the transferee. 株式会社ミカレア is a group company of Kobelco Eco-Solutions.
Kobelco Eco-Solutions: Headquartered in Chuo-ku, Kobe, Hyogo Prefecture, and led by President Okumura Hideki (奥村英樹). It is the transferor of the EOD-1 strain-related business it develops and sells. 株式会社ミカレア: A group company of Kobelco Eco-Solutions. Other details are not disclosed.
Notification numbers for Foods with Function Claims: K250 and J814. Patents have been obtained or are pending in more than 15 countries, but the patent numbers and expiry dates are not disclosed.
The disclosure states that the transaction is expected to accelerate the development of functional ingredients and applications, strengthen intellectual property protection, enhance the ability to propose B2B ingredient sales, and reinforce the supply structure. Specific amounts or percentages of the impact on results are not disclosed.
The company does not address Contract Value / Offering price.
Fuji Keizai Co., Ltd., H・B Foods Marketing Handbook 2026
Research by euglena Co., Ltd. (as of April 2026)
Article published in the Journal of Functional Foods (2023)
| Item | Details |
|---|---|
| Names of Products / Services Covered | Microalgae Euglena, EOD-1 strain, Paramylon derived from the EOD-1 strain, Golden Euglena, Mikarea's Paramylon |
| Counterparty | Kobelco Eco-Solutions Co., Ltd. (Kobelco Eco-Solutions group company: 株式会社ミカレア) |
| Counterparty overview | Kobelco Eco-Solutions: Headquartered in Chuo-ku, Kobe, Hyogo Prefecture, and led by President Okumura Hideki (奥村英樹). It is the transferor of the EOD-1 strain-related business it develops and sells. 株式会社ミカレア: A group company of Kobelco Eco-Solutions. Other details are not disclosed. |
| Relationship with the Company | Business transfer from Kobelco Eco-Solutions to euglena. Kobelco Eco-Solutions is the transferor, and euglena is the transferee. 株式会社ミカレア is a group company of Kobelco Eco-Solutions. |
| Launch date | Planned for early May 2026 (planned business transfer date). Sales of EOD-1 strain powder as an ingredient and OEM supply are planned, but the specific start date is not disclosed. A replacement product is planned for launch within approximately six months. |
| Applicable area | Maintaining immune function, Reducing feelings of fatigue, Improving sleep quality, Relieving stress, Food and supplements, B2B ingredient sales, OEM offering |
| Registration number and expiry date | Notification numbers for Foods with Function Claims: K250 and J814. Patents have been obtained or are pending in more than 15 countries, but the patent numbers and expiry dates are not disclosed. |
| Quantitative Effects | Paramylon content of at least 70%. Existing purified paramylon has a content of at least 80%. A 12-week intake study involving healthy adult men and women reported suppression of cold-like symptoms, maintenance of CD80 expression on monocytes, and increased CD28 expression on CD4⁺/CD8⁺ naive T cells. |
| Impact on Business Performance | The disclosure states that the transaction is expected to accelerate the development of functional ingredients and applications, strengthen intellectual property protection, enhance the ability to propose B2B ingredient sales, and reinforce the supply structure. Specific amounts or percentages of the impact on results are not disclosed. |
| Source | Fuji Keizai Co., Ltd., H・B Foods Marketing Handbook 2026, Research by euglena Co., Ltd. (as of April 2026), Article published in the Journal of Functional Foods (2023) |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To integrate the immune function claims and research results for paramylon derived from the EOD-1 strain, together with indoor tank cultivation technology, into existing research and product development, thereby strengthening the development of functional ingredients and applications, intellectual property protection, the ability to propose B2B ingredient sales, and the supply structure.